Guillain-Barré syndrome: surveillance and cost of treatment strategies - Authors' reply

Affiliations

¹ Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Electronic address: hugh.willison@glasgow.ac.uk.
² Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
³ Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

Comment

Hugh J Willison et al. Lancet. 2017.

. 2017 Jan 21;389(10066):253-254.

doi: 10.1016/S0140-6736(17)30055-7. Epub 2017 Jan 20.

¹ Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Electronic address: hugh.willison@glasgow.ac.uk.
² Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
³ Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

No abstract available

Comment on

Guillain-Barré syndrome: surveillance and cost of treatment strategies.
Buenz EJ, Parry GJ, Ranta A. Buenz EJ, et al. Lancet. 2017 Jan 21;389(10066):253. doi: 10.1016/S0140-6736(17)30047-8. Epub 2017 Jan 20. Lancet. 2017. PMID: 28118916 No abstract available.